Search - tctmd.com

Displaying 141 - 160 of 211

Sort: Relevancy | Date

News Daily News

Women Treated for Acute HF Report Worse QoL Than Men

Caitlin E. Cox

March 12, 2021

News Daily News

Women’s Risk for CVD Seen at Lower BP Thresholds Than Men

L.A. McKeown

February 24, 2021

News Daily News

New FDA Indication Opens Up Use of Sacubitril/Valsartan in HFpEF

Todd Neale

February 16, 2021

News Opinion CV Team Dispatch

February 2021 News Roundup

L.A. McKeown

February 01, 2021

News Daily News

Despite COVID-19, Heart Disease Remains Top US Killer: AHA

Michael O'Riordan

January 28, 2021

News Daily News

Hospitalization for HF After Acute MI More Common in Women Than Men

L.A. McKeown

January 15, 2021

News Daily News

More Women Than Men Develop HF or Die After STEMI

L.A. McKeown

December 01, 2020

News Conference News AHA 2020

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

Michael O'Riordan

November 17, 2020

News Daily News

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

Michael O'Riordan

September 24, 2020

News Daily News

Recurrent Events After MI Show Enduring Gender, Racial Gaps in Care

Shelley Wood

September 22, 2020

News Daily News

New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts

Michael O'Riordan

August 06, 2020

News Daily News

Higher Risk of HF After ACS for Women Previously on Beta-blockers

Michael O'Riordan

July 16, 2020

News Daily News

Too Many HF Trial Results Underreported or Never Published

L.A. McKeown

June 23, 2020

News Conference News HRS 2020

Subcutaneous ICD Holds Up Well Against Transvenous Devices

Todd Neale

May 13, 2020

News Daily News

COVID-19, ACE Inhibitors, and ARBs: Multiple Studies Show No Increased Risk

Michael O'Riordan

May 05, 2020

News Features

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

Michael O'Riordan

April 07, 2020

News Daily News

Heart Failure Itself, Not Just the Hospital Stay, May Raise Long-term VTE Risk

Caitlin E. Cox

January 14, 2020

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

Todd Neale

December 10, 2019

News Conference News AHA 2019

Sex Differences, EF Thresholds Probed for Sacubitril/Valsartan in Heart Failure

Shelley Wood

November 22, 2019

Advertisement

Women Treated for Acute HF Report Worse QoL Than Men

Women’s Risk for CVD Seen at Lower BP Thresholds Than Men

New FDA Indication Opens Up Use of Sacubitril/Valsartan in HFpEF

February 2021 News Roundup

Despite COVID-19, Heart Disease Remains Top US Killer: AHA

Hospitalization for HF After Acute MI More Common in Women Than Men

More Women Than Men Develop HF or Die After STEMI

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

Recurrent Events After MI Show Enduring Gender, Racial Gaps in Care

New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts

Higher Risk of HF After ACS for Women Previously on Beta-blockers

Too Many HF Trial Results Underreported or Never Published

Subcutaneous ICD Holds Up Well Against Transvenous Devices

COVID-19, ACE Inhibitors, and ARBs: Multiple Studies Show No Increased Risk

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

Heart Failure Itself, Not Just the Hospital Stay, May Raise Long-term VTE Risk

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

Sex Differences, EF Thresholds Probed for Sacubitril/Valsartan in Heart Failure

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content